SGLT-2is Mitigate Risk of Cardiovascular, Kidney Diseases in

Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.

Related Keywords

Taiwan , Researchgate Heng Chih Pan , Keelung Chang Gung , Heng Chih Pan , Chang Gung Research Database , National Kidney Foundation , Us Centers For Disease , Disease Control , Keelung Chang Gung Memorial Hospital , Chang Gung Research , Glucose Cotransport Protein , Patients With Type , Acute Kidney , Chronic Kidney Disease , Does Type , Increase Your Risk , Accessed January , Sodium Glucose Cotransport Protein 2 Inhibitors , Sglt 2i , Acute Kidney Injury , Saki , Acute Kidney Disease , Enakd , Ckd , Type 2 Diabetes ,